Biomarin Pharmaceutical (BMRN) Accumulated Depreciation & Amortization: 2010-2025
Historic Accumulated Depreciation & Amortization for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Sep 2025 value amounting to $18.5 million.
- Biomarin Pharmaceutical's Accumulated Depreciation & Amortization fell 2.73% to $18.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.7 million, marking a year-over-year decrease of 17.01%. This contributed to the annual value of $96.4 million for FY2024, which is 7.63% down from last year.
- According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Accumulated Depreciation & Amortization is $18.5 million, which was down 0.41% from $18.6 million recorded in Q2 2025.
- Biomarin Pharmaceutical's Accumulated Depreciation & Amortization's 5-year high stood at $28.0 million during Q1 2021, with a 5-year trough of $18.5 million in Q3 2025.
- For the 3-year period, Biomarin Pharmaceutical's Accumulated Depreciation & Amortization averaged around $23.6 million, with its median value being $25.4 million (2023).
- As far as peak fluctuations go, Biomarin Pharmaceutical's Accumulated Depreciation & Amortization climbed by 9.40% in 2023, and later dropped by 29.85% in 2025.
- Over the past 5 years, Biomarin Pharmaceutical's Accumulated Depreciation & Amortization (Quarterly) stood at $26.0 million in 2021, then fell by 5.51% to $24.6 million in 2022, then climbed by 9.40% to $26.9 million in 2023, then fell by 12.11% to $23.6 million in 2024, then declined by 2.73% to $18.5 million in 2025.
- Its Accumulated Depreciation & Amortization was $18.5 million in Q3 2025, compared to $18.6 million in Q2 2025 and $22.1 million in Q1 2025.